Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,291,049 papers from all fields of science
Search
Sign In
Create Free Account
sacubitril 49 MG / valsartan 51 MG Oral Tablet [Entresto]
Known as:
Entresto (sacubitril 49 MG / valsartan 51 MG) Oral Tablet
, Entresto 49 MG / 51 MG Oral Tablet
, SACUBITRIL 49 mg / VALSARTAN 51 mg ORAL TABLET, FILM COATED [ENTRESTO]
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
16 relations
Crospovidone
Entresto
HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED
Magnesium stearate
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Sacubitril/Valsartan (Entresto®)-Induced Hyponatremia
Ilana Fuzaylova
,
C. Lam
,
Om Talreja
,
A. Makaryus
,
D. Ahern
,
M. Cassagnol
Journal of pharmacy and practice
2020
Corpus ID: 73454720
Sacubitril/valsartan (Entresto®) is the first commercially available angiotensin receptor neprilysin inhibitor (ARNI) approved…
Expand
2020
2020
[Therapeutic revolution in heart failure].
A. Ancion
,
M. Nguyen Trung
,
J. Tridetti
,
P. Lancellotti
Revue Medicale de Liege
2020
Corpus ID: 219311864
The introduction of basic treatment for heart failure dates to the late 1990s. Since that time, apart from a few new developments…
Expand
2019
2019
Optimale RAAS-Dosis möglich
A. Ameri
MMW - Fortschritte der Medizin
2019
Corpus ID: 195342074
_ Patienten, die wegen einer dekompensierten Herzinsu zienz hospitalisiert werden, sollten schon im Krankenhaus auf den ARNI…
Expand
2019
2019
Risiken von Herzinsuffizienten werden gesenkt
Joana Schmidt
MMW - Fortschritte der Medizin
2019
Corpus ID: 199551483
_ In den USA und in Europa gab es bereits 2014 mehr als eine Million Hospitalisierungen wegen Herzinsuzienz – Tendenz steigend…
Expand
2018
2018
Sacubitril-Valsartan versus Standard Anti-Hypertensives in Left Ventricular Assist Device Patients
Erika Nicolsen
,
Lisa Curran
,
+6 authors
Dalton S. Mclean
Journal of Cardiac Failure
2018
Corpus ID: 81862629
2018
2018
Nouvelles thérapies de l’insuffisance cardiaque (Entresto ® ) et problématique du dosage du BNP versus le NT-pro BNP
C. Émile
2018
Corpus ID: 81644645
Review
2018
Review
2018
Serious adverse drug reactions with sacubitril/valsartan Entresto®: a French pharmacovigilance survey
F. Moulis
,
V. Rousseau
,
+6 authors
J. Montastruc
European Journal of Clinical Pharmacology
2018
Corpus ID: 4843903
2017
2017
Duale Bronchodilatation verhindert Exazerbationen
Dagmar Jäger-Becker
MMW - Fortschritte der Medizin
2017
Corpus ID: 80010699
_ Bis zu 40% der Patienten mit chronischer Herzinsu zienz mit eingeschränkter Ejektionsfraktion (HFrEF) leiden auch an Diabetes…
Expand
2017
2017
[Sacubitril/valsartan, a new and effective treatment for heart failure with reduced ejection fraction].
M. Senni
,
B. Trimarco
,
M. Emdin
,
L. De Biase
Giornale italiano di cardiologia
2017
Corpus ID: 25406835
Despite significant therapeutic advances, patients with chronic heart failure and reduced ejection fraction (HFrEF) remain at…
Expand
Review
2016
Review
2016
Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction
P. L. McCormack
Drugs
2016
Corpus ID: 19999909
Sacubitril/valsartan (Entresto™; LCZ696) is an orally administered supramolecular sodium salt complex of the neprilysin inhibitor…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE